Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ IFNA13 Monoclonal Antibody (01)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA528977
Description
This product is preservative free. It is recommended to add sodium azide to avoid contamination (final concentration 0.05%-0.1%). This antibody has specificity for Cynomolgus IFNA13.
Interferon alpha (IFN alpha) is a Type I interferon belonging to a family of structurally related, species-specific proteins exclusive to vertebrates. The interaction of IFN-alpha with its receptor component results in the activation of a number of signaling pathways which are mainly involved in innate immune response against viral infection. In humans, the gene is located on on chromosome 9. The type I interferons consist of 14 different alpha isoforms (subtypes with slightly different specificities), and single beta, omega, epsilon and kappa isoforms. Homologous molecules are found in many species, including rats and mice (and most mammals), and have been identified in birds, reptiles and fish species. Interferon alpha is produced primarily by plasmacytoid dendritic cells and is a potent component of the anti viral innate immune response; it modulates adaptive immunity.
Specifications
IFNA13 | |
Monoclonal | |
1 mg/mL | |
PBS with no preservative | |
Mouse | |
Protein A | |
RUO | |
Cynomolgus Monkey | |
Antibody | |
IgG1 |
ELISA | |
01 | |
Unconjugated | |
IFNA1; IFNA13; IFN-alpha 1b; IFN-alpha-1/13; Interferon; interferon alpha 13; interferon alpha 1b; interferon alpha-1/13; Interferon alpha-D; interferon, alpha 13; interferon-alpha1; leIF D | |
Recombinant Cynomolgus IFNA13 protein. | |
100 μL | |
Primary | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction